NCT07615348

CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-06-10Est. Completion: 2028-08-10

Enrollment target: 75 participants

Locations

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China

Contact

Le Qu, Ph.D.septsoul@hotmail.com +86 15720625951

Other microbiome trials you might be interested in

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Phase 2Recruiting

Metastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8TFE3-Rearranged Renal Cell CarcinomaUnresectable Renal Cell Carcinoma

This phase II trial studies how well axitinib and nivolumab work in treating patients with TFE/translocation renal cell …

Birmingham, United StatesEst. completion Sep 30, 2024

View Trial →

To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal CancerPhase 1Recruiting

Renal Cell Carcinoma (RCC)

This is a single-arm, open-label, dose-escalating Phase 1 clinical study. It aims to evaluate the safety, tolerability a…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.